PhaseBio: SFJ Says PhaseBio Must Return Rights to Lead Program
PhaseBio Pharmaceuticals reported its collaboration partner, SFJ Pharmaceuticals Group, informed the company it would need to return the rights to its lead program.
Read full article »
PhaseBio is a biopharmaceutical firm that researches and develops novel therapeutics for the treatment of orphan diseases.
Read more